

Financial Tear Sheet

Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Stock Information

XBIT (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$4.79
Change (%)	▲ 0.03 (0.63%)
Volume	28,819
52 Week Low	\$2.77
Market Cap	\$169,746,928
Rolling EPS	-1.26
PE Ratio	0
Shares Outstanding	35,437,772
Data as of 02/23/18 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

Date	Title
01/26/18	XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
01/25/18	XBiotech Publishes Results in PLOS ONE for its True Human Antibody 514G3 Targeting S. aureus
01/19/18	XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/14/18	SC 13G/A
02/14/18	SC 13G/A
02/14/18	SC 13G/A
01/19/18	8-K

Management

John Simard	Founder, President, Chief Executive Officer & Chairman
Norma I. Gonzalez	Vice President of Quality
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Chief Scientific Officer
Michael Stecher, M.D.	Medical Director

Primary IR Contact

James S. Whitehurst
XBiotech
Phone: +1 512.386.2993
Email: swhitehurst@xbiotech.com

Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Thorpe McKenzie	Director